Q-linea AB (QLINEA) AI Stock Analysis

Q-linea AB

(Nasdaq OMX AB:QLINEA)

Select Model

Rating:39Underperform

Price Target:SEK 14.00▼(-3.78% Downside)

Action:downgraded

Date:11/01/26

Persistent losses and negative cash flow are the primary weaknesses, reinforced by bearish price trends and an unhelpful negative P/E ratio. Oversold technical readings and positive equity with low leverage provide limited support, resulting in a weak overall score.

Positive Factors

Revenue GrowthRevenue growth indicates that Q-linea is achieving some commercial traction in infectious-disease diagnostics, despite its small base. If this expansion continues, greater instrument and consumable adoption could improve operating leverage and provide a foundation for future profitability.

Negative Factors

Persistent UnprofitabilityDeeply negative gross profit shows that Q-linea is not yet covering the direct economics of its business, while operating and net losses indicate additional costs remain unsupported by revenue. This weak profitability limits internally funded growth and makes sustainable earnings dependent on substantial improvement in economics.

Q-linea AB (QLINEA) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 282.34M
Dividend Yield: ―
Average Volume (3M): 7,154
Price to Earnings (P/E): -1.7
Beta (1Y): 2.73
Revenue Growth: 33.26%
EPS Growth: 90.73%
Country: Sweden
Employees: 70
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Specialties

Q-linea AB Business Overview & Revenue Model

Company Description

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicr...

Q-linea AB Financial Statement Overview

Summary

Revenue grew 13.5% and the balance sheet has positive equity with low leverage, but severe operating losses, negative margins, negative operating cash flow, negative free cash flow, and continued cash burn indicate significant financial weakness.

Income Statement

8Very Negative

Balance Sheet

65Positive

Cash Flow

12Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	11.19M	11.10M	2.36M	4.44M	12.79M	9.34M
Gross Profit	-202.80M	-180.02M	-11.11M	995.00K	-21.38M	-25.03M
EBITDA	-126.04M	-160.54M	-195.40M	-210.99M	-252.69M	-218.48M
Net Income	-139.77M	-182.49M	-216.87M	-229.37M	-275.77M	-233.18M
Balance Sheet
Total Assets	276.52M	369.67M	147.99M	231.98M	207.39M	466.63M
Cash, Cash Equivalents and Short-Term Investments	150.71M	258.11M	25.66M	81.89M	72.62M	166.03M
Total Debt	16.86M	5.84M	151.21M	20.56M	20.93M	79.00K
Total Liabilities	31.37M	31.66M	175.45M	42.34M	45.76M	35.84M
Stockholders Equity	245.15M	338.00M	-27.46M	189.64M	161.63M	430.79M
Cash Flow
Free Cash Flow	-72.28M	-169.68M	-187.49M	-236.86M	-268.11M	-267.02M
Operating Cash Flow	-133.97M	-162.12M	-182.50M	-228.52M	-250.86M	-255.05M
Investing Cash Flow	-93.84M	-7.22M	-5.04M	-7.77M	315.25M	-23.82M
Financing Cash Flow	250.81M	402.12M	131.27M	245.41M	-6.60M	283.81M

Q-linea AB Technical Analysis

Technical Analysis SentimentNegative

Last Price14.55

Price Trends

50DMA17.38Negative

100DMA17.45Negative

200DMA19.56Negative

Market Momentum

MACD-0.73Positive

RSI23.62Positive

STOCH21.13Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLINEA, the sentiment is Negative. The current price of 14.55 is below the 20-day moving average (MA) of 16.06, below the 50-day MA of 17.38, and below the 200-day MA of 19.56, indicating a bearish trend. The MACD of -0.73 indicates Positive momentum. The RSI at 23.62 is Positive, neither overbought nor oversold. The STOCH value of 21.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:QLINEA.

Q-linea AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:QLINEA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CEVI	83Outperform	SEK 4.67B	33.11	15.23%	1.44%	1.95%	-8.91%
SE:SEZI	57Neutral	SEK 532.17M	-5.30	-35.44%	―	18.56%	28.11%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ALZ	43Neutral	SEK 112.04M	-1.62	-17.52%	―	-100.00%	20.94%
SE:ACARIX	40Underperform	SEK 223.04M	-5.29	-100.09%	―	65.82%	41.28%
SE:QLINEA	39Underperform	SEK 282.34M	-1.69	-48.10%	―	33.26%	90.73%
SE:BOUL	38Underperform	SEK 40.19M	-2.23	-58.52%	―	-16.09%	78.68%

* Healthcare Sector Average

Performance Comparison

SE:QLINEA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:QLINEA	Q-linea AB	14.55	-10.68	-42.33%
SE:BOUL	Boule Diagnostics AB	1.00	-5.40	-84.38%
SE:CEVI	CellaVision AB	191.40	17.86	10.29%
SE:SEZI	Senzime AB	3.29	-2.33	-41.55%
SE:ALZ	Alzinova AB	0.34	-1.08	-75.98%
SE:ACARIX	Acarix AB	0.18	-0.09	-32.58%

Q-linea AB Corporate Events

Q-linea grows ASTar footprint but U.S. adoption slows revenue targets

Oct 30, 2026

Q-linea reported modest growth in net sales for the first nine months of 2026, driven by increasing consumables usage on its ASTar instruments, while still posting significant operating losses. The company improved its net cash position and kept mont...

Q-linea Appoints New CFO to Support Growth in Rapid Infection Diagnostics

Aug 20, 2026

Q-linea AB, a Swedish infection diagnostics specialist listed on Nasdaq Stockholm, develops rapid testing technologies to improve treatment of severe infections, notably through its automated ASTar platform that accelerates antibiotic susceptibility...

Q-linea secures Premier contract to accelerate U.S. rollout of ASTar system

Aug 18, 2026

Q-linea AB, a Swedish infection diagnostics specialist listed on Nasdaq Stockholm, develops rapid testing solutions for infectious diseases with a core focus on rapid antibiotic susceptibility testing. Its flagship ASTar platform is designed to provi...

Q-linea Secures Key U.S. Health System Deal for ASTar Rapid Infection Diagnostics

Aug 10, 2026

Q-linea AB, a Sweden-based infection diagnostics specialist listed on Nasdaq Stockholm, develops rapid Antibiotic Susceptibility Testing solutions that enable faster and more targeted treatment of severe infections such as sepsis. Its core product, t...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 01, 2026

Q-linea AB AI Stock Analysis